Olga K. Vikulova, М. В. Шестакова
Abstract
The safety of antidiabetic medications has received much attention in the resent past. Although concerns on the safety of glibenclamide therapy iscontroversial, some studies showed an increased risk of cardiovascular morbidity (f.e. myocardial infarction) and risk of mortality in subjects usingglibenclamide, but not other SU (gliclazide or glimepiride)
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The safety of antidiabetic medications has received much attention in the resent past. Although concerns on the safety of glibenclamide therapy iscontroversial, some studies showed an increased risk of cardiovascular morbidity (f.e. myocardial infarction) and risk of mortality in subjects usingglibenclamide, but not other SU (gliclazide or glimepiride)
Key concepts: Medicine, Glimepiride, Glibenclamide, Gliclazide, Myocardial infarction, cons, Intensive care medicine, Diabetes mellitus